media – Page 125 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations, visual evaluations, or immunological tests, all of which depend on the presence of advanced symptoms that might take months or even years to appear. Consequently, many cases remain untreated and undiagnosed early on, complicating treatment and leading to the severe, long-term impacts of Lyme disease. Now, a groundbreaking patented molecular diagnostic kit is poised to provide game-changing autonomous detection of Lyme disease within minutes. Presently, Lyme disease testing methods aim to identify antibodies produced by the body in reaction to the infection. However, since the development of these antibodies can take several weeks, tests performed soon after infection often yield false negatives. En Carta Diagnostics (Paris, France) has developed a molecular diagnostic platform that effectively addresses this issue. This platform, which utilizes a simple ...
- Source: drugdu
- 102
- June 4, 2024
GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO

GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.A GSK multiple myeloma drug that was withdrawn from the market is accumulating new clinical data that could support its return — perhaps as an earlier line of therapy. With the latest results, clinicians and GSK executives say they may have figured out how to address a lingering question about how to safely dose the drug, Blenrep. The new data were presented Sunday during the annual meeting of the American Society of Clinical Oncology in Chicago. Blenrep is an antibody drug conjugate (ADC) that targets the BCMA protein on multiple myeloma cells, delivering to them a payload of toxic chemotherapy. There are many multiple myeloma drugs available, but frequent relapse in this ...
- Source: drugdu
- 133
- June 4, 2024
Scemblix Shows Improved Major Molecular Response Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Don Tracy, Associate Editor Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Novartis announced promising results from the Phase III ASC4FIRST trial of Scemblix (asciminib), which showed superiority over standard-of-care tyrosine kinase inhibitors (TKIs) in treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). “Patients living with CML need efficacious and well-tolerated treatment options that help them achieve meaningful outcomes as they manage their chronic condition,” said Shreeram Aradhye, MD, president, development, chief medical officer, Novartis, in a press release. “The compelling ASC4FIRST data highlight the potential of Scemblix to achieve better results than standard-of-care in newly diagnosed adults, while maintaining a favorable safety and tolerability profile. These results reinforce Scemblix as a proven treatment in Ph+CML-CP, as we continue to build on ...
- Source: drugdu
- 123
- June 4, 2024
Leads Biolabs’ Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.

NANJING, China, June 3, 2024 /PRNewswire/ — The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigorous evaluation by Scientific Program Committee and ASCO Leadership, LBL-024, a bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, was selected for an oral presentation. Today, Dr. Panpan Zhang, the investigator of LBL-024, presented the outstanding clinical data during the Clinical Science Symposium-Building Novel Antibody-Based Approaches in Gastrointestinal Cancers. This is a phase I/II first in human, open-label, multicenter, dose escalation/expansion study that evaluates the safety and efficacy of LBL-024 monotherapy in patients with advanced malignant tumors and neuroendocrine carcinoma. The study results demonstrated good safety profile and very promising antitumor effects as a monotherapy in patients with advanced malignant tumors, particularly extrapulmonary neuroendocrine ...
- Source: drugdu
- 158
- June 4, 2024
EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has granted AbbVie’s ulcerative colitis (UC) drug Skyrizi (risankizumab) a positive recommendation for approval. The committee’s recommendation was based on results from two Phase III studies. In the INSPIRE trial (NCT03398148), 20.3% of patients in the Skyrizi treatment group achieved clinical remission, compared to 6.2% in the placebo group. Furthermore, in the Phase III COMMAND study (NCT03398135), 51% of patients treated with Skyrizi 180 mg and 48% of patients treated with Skyrizi 360mg demonstrated endoscopic improvement in week 52. Skyrizi is a monoclonal antibody therapy that inhibits interleukin-23 (IL-23). This reduces anti-inflammatory processes. In the 31 May press release, Dr Edouard Louis, the head of gastroenterology at University Hospital CHU of Liège Belgium said: “These results suggest that risankizumab may help patients coping with the challenging symptoms of ulcerative colitis, which include abdominal pain, bowel urgency and ...
- Source: drugdu
- 118
- June 4, 2024
NHS platform announced to accelerate personalised cancer vaccine clinical trials

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines The NHS has announced that it has treated its first patient in England with a personalised cancer vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad (CVLP). Following the launch of the trial, thousands of cancer patients in England are set to be fast-tracked to access personalised cancer vaccines to help find new life-saving treatments. In partnership with Genomics England, the NHS CVLP will help speed up access to mRNA-personalised cancer vaccine clinical trials for cancer patients while accelerating the development of cancer vaccines as a form of treatment. With 30 hospitals in England already signed up to participate, the scheme intends to collaborate with the pharmaceutical industry to include patients across many cancer types. Taking place in several NHS trusts across the country to treat different types of ...
- Source: drugdu
- 81
- June 4, 2024
The Crick announces new partnerships with SMEs and MRC for research

The projects will focus on a range of research areas, including Down’s syndrome and ALS The Francis Crick Institute has announced six new partnerships with small and medium-sized enterprises (SMEs) with support from the Medical Research Council (MRC) focused on innovative discovery projects led by Crick researchers. Supported by an MRC Business Engagement Fund Award, as part of UK Research and Innovation, the collaborations will focus on the application of novel cutting-edge technologies, encompassing a diverse range of research to deliver impactful outcomes. Paul Mercer, head of collaboration, the Crick, commented: “We are… excited to be able to develop these research partnerships with SMEs, diversifying the opportunity for development of Crick discoveries through the application of disruptive innovations.” Partners include Perha Pharmaceuticals, Scalable Minds, Broken String Biosciences, Hertility Health, Automata Technologies and Mytos. The projects will focus on a range of research, including pharmacological treatments for congenital heart defects in ...
- Source: drugdu
- 92
- June 4, 2024
Existing drug alleviates symptoms of a rare genetic syndrome

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1). Researchers identified the treatment based on their discovery that the syndrome is linked to elevated levels of interferon-gamma (IFN-gamma), a protein involved in immune system responses, providing new insights into the role of IFN-gamma in autoimmunity. The study, led by researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, was published today in the New England Journal of Medicine. In a three-stage study, conducted in mice and people, the researchers examined how APS-1 causes autoimmune disease. The syndrome is marked by dysfunction of multiple organs, usually beginning in childhood, and is fatal in more than 30% of cases. This inherited syndrome is caused by a deficiency in a gene that keeps the immune system’s T cells from attacking cells of ...
- Source: drugdu
- 125
- June 3, 2024
Better sleep health associated with lower levels of loneliness

A new study to be presented at the SLEEP 2024 annual meeting found that better sleep health was associated with lower levels of loneliness, and this association was stronger among younger adults. Results indicate that better sleep health was associated with significantly lower total loneliness, emotional loneliness and social loneliness. While better sleep health was associated with lower total and emotional loneliness across ages, this association was stronger for younger adults. However, age did not moderate the association between sleep health and social loneliness. “Loneliness is an urgent public health crisis, and there is a pressing need for providers to better understand and treat it,” said lead author and principal investigator Joseph Dzierzewski, who has a doctorate in clinical psychology and is vice president of research at the National Sleep Foundation in Washington, D.C. “Our results highlight the important role that sleep plays in understanding loneliness across the adult lifespan. ...
- Source: drugdu
- 94
- June 3, 2024
AstraZeneca actively promotes Shanghai to become the “home port” for the export of pharmaceutical innovation achievements

What is the significance of the Chinese market to leading biopharmaceutical companies? Pablo Soriot, global CEO of AstraZeneca, one of the leading international biopharmaceutical companies, told reporters in an interview on the 26th: “China plays a vital role in the global healthcare industry. It is not only a leader in innovation, but also plays a key role in the global research and development and production of important drugs. For AstraZeneca, the Chinese market is crucial.”Biopharmaceutical Industry International Development Conference” held on the same day , AstraZeneca officially announced that Shanghai would become its fifth global strategic center. The “Shanghai Biopharmaceutical Innovation Enterprise 2024 Overseas Cooperation Plan” was officially released on the same day, enabling local innovative drugs to reach a new level and helping Chinese innovation lead global pharmaceutical innovation. It is reported that in the future, Shanghai, China will become another global strategic center integrating R&D, commercial and production ...
- Source: drugdu
- 106
- June 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.